These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34462794)

  • 41. The lightning-fast quest for COVID vaccines - and what it means for other diseases.
    Ball P
    Nature; 2021 Jan; 589(7840):16-18. PubMed ID: 33340018
    [No Abstract]   [Full Text] [Related]  

  • 42.
    Johnson BJ; Van Abel KM; Ma DJ; Johnson DR
    J Nucl Med; 2021 Oct; 62(10):1483-1484. PubMed ID: 33741644
    [No Abstract]   [Full Text] [Related]  

  • 43. SARS-CoV-2 immunogenicity in individuals infected before and after COVID-19 vaccination: Israel, January-March 2021.
    Abu Jabal K; Ben-Amram H; Beiruti K; Brimat I; Abu Saada A; Bathish Y; Sussan C; Zarka S; Edelstein M
    Epidemiol Infect; 2021 Aug; 149():e239. PubMed ID: 34399868
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Why Fast COVID-19 Vaccination Needed for People with Disabilities and Autistics in Korea?
    Yoon WH
    J Korean Med Sci; 2021 Sep; 36(37):e267. PubMed ID: 34581522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. COVID-19 vaccines: ethical framework concerning human challenge studies.
    Calina D; Hartung T; Docea AO; Spandidos DA; Egorov AM; Shtilman MI; Carvalho F; Tsatsakis A
    Daru; 2020 Dec; 28(2):807-812. PubMed ID: 32851596
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Vaccination immunology in SARS-CoV-2].
    Helweg-Larsen J; Benfield T
    Ugeskr Laeger; 2021 Mar; 183(11):. PubMed ID: 33734074
    [TBL] [Abstract][Full Text] [Related]  

  • 47. COVID-19 vaccination in cancer patients: Is it the time or should we wait?
    Arambulo S; Cabezas-Camarero S; Rojas H; Sotelo MJ
    J Cancer Res Ther; 2021; 17(6):1588-1589. PubMed ID: 34916405
    [No Abstract]   [Full Text] [Related]  

  • 48. Maternal COVID-19, vaccination safety in pregnancy, and evidence of protective immunity.
    Pham A; Aronoff DM; Thompson JL
    J Allergy Clin Immunol; 2021 Sep; 148(3):728-731. PubMed ID: 34314761
    [No Abstract]   [Full Text] [Related]  

  • 49. [COVID-19 vaccination for cancer patients: Medical and ethical need].
    Spano JP; Barre-Sinoussi F; Kieny MP; Marcelin AG; Blay JY
    Bull Cancer; 2021 Mar; 108(3):225-227. PubMed ID: 33674059
    [No Abstract]   [Full Text] [Related]  

  • 50. Sars-Cov-2 virus and vaccination; biological and statistical framework.
    Arslan F; Ankaralı H
    Expert Rev Vaccines; 2021 Sep; 20(9):1059-1063. PubMed ID: 34365880
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Can immune responses predict which vaccines work best?
    Cohen J
    Science; 2021 Jul; 373(6551):142-143. PubMed ID: 34244387
    [No Abstract]   [Full Text] [Related]  

  • 52. COVID-19 vaccine development: What lessons can we learn from TB?
    Safar HA; Mustafa AS; McHugh TD
    Ann Clin Microbiol Antimicrob; 2020 Nov; 19(1):56. PubMed ID: 33256750
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 54. COVID-19 vaccine trials must include helminth-infected cohorts.
    Egwang TG; Owalla TJ; Kemigisha M
    Nat Immunol; 2022 Feb; 23(2):148. PubMed ID: 35075281
    [No Abstract]   [Full Text] [Related]  

  • 55. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern.
    Yue L; Zhou J; Zhou Y; Yang X; Xie T; Yang M; Zhao H; Zhao Y; Yang T; Li H; Xiang H; Wang J; Lu S; Liu H; Zhao H; Wei X; Zhang Y; Xie Z
    Emerg Microbes Infect; 2021 Dec; 10(1):2125-2127. PubMed ID: 34666622
    [No Abstract]   [Full Text] [Related]  

  • 57. Current and future nanoparticle vaccines for COVID-19.
    Vu MN; Kelly HG; Kent SJ; Wheatley AK
    EBioMedicine; 2021 Dec; 74():103699. PubMed ID: 34801965
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trials for second generation Covid-19 vaccines: Revisiting the debate over placebo use in developing country clinical trials.
    Lurie P
    Indian J Med Ethics; 2021; VI(2):1-10. PubMed ID: 33908352
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COVID-19 vaccines: A race against time.
    Peiffer-Smadja N; Rozencwajg S; Kherabi Y; Yazdanpanah Y; Montravers P
    Anaesth Crit Care Pain Med; 2021 Apr; 40(2):100848. PubMed ID: 33774261
    [No Abstract]   [Full Text] [Related]  

  • 60. Inclusion of pregnant individuals among priority populations for coronavirus disease 2019 vaccination for all 50 states in the United States.
    Grünebaum A; McCullough LB; Litvak A; Chervenak FA
    Am J Obstet Gynecol; 2021 May; 224(5):536-539. PubMed ID: 33545113
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.